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OBJECTIVES: To evaluate health care costs following acute coronary syndromes 
(ACS) in patients with/without recurrent cardiovascular events (CVEs). 
METHODS: Patients with ≥1 ICD-9 CM codes for acute myocardial infarction 
(410.xx) or unstable angina (411.1x) during ACS hospitalization were identified 
from the HealthCore Integrated Research Database January 1, 2006 to September 
30, 2011 (index event date defined as first ACS hospitalization date). Patients 
with <12 months pre/post-index plan eligibility or <18 years old were excluded. 
Recurrent CVEs were defined as myocardial infarction, non-fatal stroke or 
coronary heart disease-related mortality. Total and CV-related hospitalization 
costs following index ACS were evaluated in patients with/without recurrent 
CVEs, adjusting for demographic characteristics, comorbidities, treatment 
utilization and index ACS characteristics. RESULTS: Of 140,903 US patients, 22.0% 
had ≥1 subsequent CVE during follow-up. Patients with versus without recurrent 
CVEs were older - and had more comorbidities. Mean (median) follow-up was 2.0 
(1.6) and 1.9 (1.5) years in patients with and without recurrent CVEs, respectively. 
Mean (median) length of stay for index ACS hospitalization was longer in 
patients with versus without recurrent CVEs. Mean (median) 1-year post-index 
total and CV-related cost were higher in patients with versus without recurrence 
($41,478 [$17,474] and $34,094 [$10,057] versus $30,608 [$17,241] and $23,613 
[$10,336]; p<0.001). Inpatient hospitalization costs were the major driver of total 
expenditures, comprising 76% and 72% of total costs in patients with versus 
without recurrence, respectively. Mean 2- and 3-year post-index total and CV-
related costs were also significantly higher in patients with recurrent CVEs (2-
year: $27,746 and $20,572 vs. $18,707 and $12,794; 3-year: $21,880 and $15,260 vs. 
$14,438 and $9,049; p<0.001). CONCLUSIONS: Following ACS hospitalization, 
patients with recurrent CVEs incurred higher 1-, 2- and 3-year post-index event 
costs compared those without recurrence, underscoring the need to focus on the 
prevention of subsequent adverse CVEs following ACS to improve patient 
outcomes and reduce total health care cost.  
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OBJECTIVES: An increasing proportion of coronary artery bypass grafting (CABG) 
surgery is performed with concomitant valve repair or replacement surgery, and 
complications related to these procedures can have significant impact on 
patients and health care systems. This study quantifies the incidence and 
clinical and economic burden of complications associated with CABG, valve and 
combined (CABG and valve) surgery in the US. METHODS: Premier Perspective 
database was used to identify patients having CABG and/or valve surgery 
between Jan 2008 to Dec 2011. The study complications were postoperative 
infection, septicemia, postoperative stroke, postoperative adult respiratory 
distress syndrome, new-onset hemodialysis, reoperation, respiratory 
complication, cardiac complication, and hemorrhage. Both surgeries and 
complications were identified by ICD-9 codes. This study investigated (1) overall 
incidence rate of any study complication, (2) differences in length of stay (LOS), 
and (3) total inpatient costs for patients with and without complications during 
index and readmission within 30 days across three procedures. For multivariate 
adjustments, Gamma-distributed generalized linear model (GLM) and Poisson-
distributed GLM models were used. RESULTS: Of 100,601 patients who 
underwent CABG alone, 31,903 (31.7%) had any study complications during their 
index or readmitted stay. Patients with valve alone or combined surgery had 
higher incidence of complications: 38.2% and 47.3% (p<0.01 for both), 
respectively. Complications in CABG incurred additional average LOS of 4.8 days 
(p<0.01) and additional average hospital cost of $14,699 (p<0.01) over CABG 
patients not experiencing complications, while complications in valve alone and 
combined surgery incurred an additional 6.8 days, $23,464 and 6.7 days, $24,985 
respectively. CONCLUSIONS: Results showed complications in CABG and/or 
valve surgery increase clinical and economic burden by 0.41 to 0.60 times in 
terms of additional LOS and hospital costs. The burden increases significantly 
when a patient has combined procedures. The results highlight the potential 
opportunity for cost reduction by preventing the complications associated with 
CABG and/or valve surgeries.  
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OBJECTIVES: Cost of illness in ischemic stroke has historically been reported as 
direct total health care cost, not compared to an equally ill, non-stroke, control 
group. This methodology likely overestimates cost and may affect national 
burden of illness estimates and cost effectiveness comparisons. The magnitude 
of the over-estimation is not known. The objective of this study is to estimate 
the 1-year marginal cost of ischemic stroke in SC Medicare beneficiaries and 
examine the impact of total versus marginal cost reporting on overall US stroke 
cost estimates and on the distribution of expenditures of inpatient care and 
rehabilitation. METHODS: Cost of illness was estimated from a Medicare cost 
perspective for ischemic stroke in South Carolina. Stroke patients were matched 
1:2 to non-stroke beneficiaries using nearest-neighbor propensity score 
matching. Standard Medicare analytic files for all beneficiaries in SC in 2004 and 
2005 were summed for the year following their index ischemic stroke or to death. 
The total study sample size was 8928. RESULTS: The use of a marginal costing 
approach produced lower estimates than the average total costing method. The 
2004 marginal costs of stroke were $26.9 million, while the average cost estimate 
was $81.3 million, a difference of $54.4 million. Average total cost includes 
expenditures for comorbid conditions which are common in patients with 
stroke. Cost of stroke for the US in 2012 would be overestimated by $4.89 billion 
if this difference is generalized to national estimates. Furthermore, the 
proportion of stroke costs attributable to rehabilitation services would change 
from 13.7% based on mean cost, to 29.3% using marginal estimates. 
CONCLUSIONS: Using a marginal costing approach to estimate health care costs 
for conditions common in patients with a high prevalence of comorbid 
conditions is essential for accurate estimation of burden of illness, as well as 
estimating in-hospital and follow-up cost distributions correctly.  
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OBJECTIVES: To estimate the costs-of-disease and direct cost components of 
thromboembolic complications associated with AF and the side-effects related 
with anticoagulant treatment, in Turkish setting. METHODS: A panel consisting 
of experts on cardiology, hematology, pulmonology and neurology, held a 
meeting to discuss the disease management processes of stroke, SE, IC bleeding 
and EC bleeding. They reviewed the global and local literature and guidelines, 
and also they discussed the spectrum of local clinical practices that are 
performed frequently. All cost components, including medications, surgical 
treatment, hospitalization, out-patient follow-up procedures and rehabilitation 
services were reviewed. September 2012 local prices for medications and 
procedures were used as sources. Mid-2012 USD currency rate was used. 
RESULTS: The cost of SE was estimated as 431 USD/event (70% non-
pharmacologic treatment cost). The cost of acute management of stroke was 
calculated as 2,517 USD, of which 76% was caused by hospital stay. The annual 
cost of follow-up of stroke patients was 799 USD/year. The source of almost half 
(48%) of the cost was non-pharmacologic treatment (namely neurologic 
rehabilitation). The cost of major EC bleeding was 1014 USD/event (48% hospital 
stay cost) and the cost of minor EC bleeding is 49 USD/event (~100% hospital stay 
cost). The cost of acute management of IC bleeding was calculated as 6166 
USD/event (86% hospital stay cost). The annual cost of follow-up of patients with 
IC bleeding was 728 USD/year (52% non-pharmacologic treatment cost). 
CONCLUSIONS: The costs of thromboembolic complications in AF patients are 
quite high. The acute events of stroke or IC bleeding are quite costly, and 
additional costs continue to happen due to treatment of neurologic disabilities 
caused by the primary event. Therefore, the economic burden of these 
thromboembolic events might be well reduced, if the prevention of these events 
could be prevented in AF patients.  
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OBJECTIVES: Venous thromboembolism (VTE), a condition that includes deep 
vein thrombosis (DVT) and pulmonary embolism (PE) is associated with major 
morbidity and mortality and causes huge economic burden. The purpose of this 
study was to evaluate direct and indirect costs of patients with VTE in China, 
producing an average cost per patient per year. METHODS: A cost-of-illness 
analyses was performed. The economic data was collected from an observational 
retrospective study. We recruited 154 patients diagnosed with VTE in Beijing, 
Shanghai and Guangzhou between October 2012 and December2012. Patients or 
their carers completed a questionnaire about resource utilization and 
absenteeism from work in the past year by an interview. Direct medical costs 
included outpatient visit, hospitalization,, ambulatory, drug, diagnostic tests, 
and physiotherapy costs. Indirect costs were estimated using a human capital 
approach. All costs referred to 2011. RESULTS: Among 154 patients, DVT 
accounted for 85.7%,51.95% were female and the mean age was 61.5±12.4. 96.8% 
patients have at least one kind of health insurance. From the societal 
perspective, total costs per patient over 1 year amounted to Chinese Yuan (CNY) 
21484 (median: CNY14039, IQR: CNY6714-CNY32036). The direct medical costs 
were CNY15899 accounting for 74% of the total. The informal care costs were 
CNY3623 accounting for 16.9% of the total. And the indirect costs were CNY1678 
accounting for 7.8%. CONCLUSIONS: The economic burden of VTE in China is 
considerable. The primary burden on patients was due to the direct medical 
costs.  
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OBJECTIVES: Atrial fibrillation (AF) increases the risk of stroke 5-fold and may be 
responsible for larger and more disabling strokes than those without AF which 
increase the associated costs of care. The purpose of this study was to evaluate 
